BACKGROUND: A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radioimmunotherapy trial was conducted to evaluate the efficacy and safety in untreated elderly diffuse large B-cell lymphoma (DLBCL) patients. PATIENTS AND METHODS: From February 2005 to April 2006, in our institute we treated 20 eligible elderly (age > or =60 years) patients with previously untreated DLBCL using a novel regimen consisting of six cycles of CHOP chemotherapy followed 6-10 weeks later by (90)Y ibritumomab tiuxetan. RESULTS: The overall response rate to the entire treatment regimen was 100%, including 95% complete remission (CR) and 5% partial remission. Four (80%) of the five patients who achieved less than a CR with CHOP improved their remission status after radioimmunotherapy. With a median follow-up of 15 months, the 2-year progression-free survival was estimated to be 75%, with a 2-year overall survival of 95%. The (90)Y ibritumomab tiuxetan toxicity included grade > or =3 hematologic toxicity in 12 of 20 patients; the most common grade > or =3 toxic effects were neutropenia (12 patients) and thrombocytopenia (7 patients). Transfusions of red blood cells and/or platelets were given to one patient. CONCLUSION: This study has established the feasibility, tolerability, and efficacy of this regimen for elderly patients with DLBCL.
BACKGROUND: A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radioimmunotherapy trial was conducted to evaluate the efficacy and safety in untreated elderly diffuse large B-cell lymphoma (DLBCL) patients. PATIENTS AND METHODS: From February 2005 to April 2006, in our institute we treated 20 eligible elderly (age > or =60 years) patients with previously untreated DLBCL using a novel regimen consisting of six cycles of CHOP chemotherapy followed 6-10 weeks later by (90)Y ibritumomab tiuxetan. RESULTS: The overall response rate to the entire treatment regimen was 100%, including 95% complete remission (CR) and 5% partial remission. Four (80%) of the five patients who achieved less than a CR with CHOP improved their remission status after radioimmunotherapy. With a median follow-up of 15 months, the 2-year progression-free survival was estimated to be 75%, with a 2-year overall survival of 95%. The (90)Y ibritumomab tiuxetan toxicity included grade > or =3 hematologic toxicity in 12 of 20 patients; the most common grade > or =3 toxic effects were neutropenia (12 patients) and thrombocytopenia (7 patients). Transfusions of red blood cells and/or platelets were given to one patient. CONCLUSION: This study has established the feasibility, tolerability, and efficacy of this regimen for elderly patients with DLBCL.
Authors: Camille E Puronen; Ryan D Cassaday; Philip A Stevenson; Brenda M Sandmaier; Mary E Flowers; Damian J Green; David G Maloney; Rainer F Storb; Oliver W Press; Ajay K Gopal Journal: Biol Blood Marrow Transplant Date: 2018-07-03 Impact factor: 5.742
Authors: Jonathan W Friedberg; Joseph M Unger; W Richard Burack; Ajay K Gopal; Robert N Raju; Auayporn P Nademanee; Mark S Kaminski; Hongli Li; Oliver W Press; Thomas P Miller; Richard I Fisher Journal: Br J Haematol Date: 2014-04-18 Impact factor: 6.998
Authors: Karin Hohloch; H K Lankeit; P L Zinzani; C W Scholz; M Lorsbach; C Windemuth-Kieselbach; L Trümper Journal: Eur J Nucl Med Mol Imaging Date: 2014-04-11 Impact factor: 9.236
Authors: John M Pagel; Nural Orgun; Donald K Hamlin; D Scott Wilbur; Theodore A Gooley; Ajay K Gopal; Steven I Park; Damian J Green; Yukang Lin; Oliver W Press Journal: Blood Date: 2009-01-05 Impact factor: 22.113